Daan Gene (002030) Fundamentals 2026 — Revenue Analysis | SniperIQ
Daan Gene (002030) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥7.3B, trading at ¥5.21 on the SHZ. This SniperIQ fundamentals page covers Daan Gene's valuation, profitability (net margin -121.3%), revenue (¥758M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daan Gene's market cap?
Daan Gene (002030) has a market capitalization of approximately ¥7.3B, trading at ¥5.21 on the SHZ. Market cap moves with the live share price.
What is Daan Gene's P/E ratio?
Daan Gene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daan Gene?
Daan Gene runs a net profit margin of -121.3%, a gross margin of 30.6%, and an operating margin of -145.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daan Gene generate?
Daan Gene reported revenue of ¥758M for fiscal year 2025, with net income of -¥744M and earnings per share (EPS) of -0.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daan Gene pay a dividend?
Daan Gene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Daan Gene financially healthy?
Daan Gene carries a debt-to-equity ratio of 0.02x and a current ratio of 2.98x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daan Gene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daan Gene (002030) the key facts are: market cap ¥7.3B, revenue ¥758M, 52-week range 4.8-8.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daan Gene's full fundamentals live
Get Daan Gene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.